The community-level interventions for pre-eclampsia (CLIP) cluster randomised trials in Mozambique, Pakistan, and India: An individual participant-level meta-analysis by Dadelszen, Peter Von et al.
eCommons@AKU 
Woman and Child Health Division of Woman and Child Health 
8-22-2020 
The community-level interventions for pre-eclampsia (CLIP) 
cluster randomised trials in Mozambique, Pakistan, and India: An 
individual participant-level meta-analysis 
Peter Von Dadelszen 
King's College London, London, UK. 
Zulfiqar Ahmed Bhutta 
Aga Khan University, zulfiqar.bhutta@aku.edu 
Sumedha Sharma 
University of British Columbia, Vancouver, BC, Canada 
Jeffrey Bone 
University of British Columbia, Vancouver, BC, Canada 
Joel Singer 
University of British Columbia, Vancouver, BC, Canada 
See next page for additional authors 
Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_wc 
 Part of the Maternal and Child Health Commons, Obstetrics and Gynecology Commons, Pediatrics 
Commons, and the Women's Health Commons 
Recommended Citation 
Dadelszen, P. V., Bhutta, Z. A., Sharma, S., Bone, J., Singer, J., Wong, H., Bellad, M. B., Goudar, S. S., Lee, T., 
Qureshi, R., CLIP Trials Working Group, . (2020). The community-level interventions for pre-eclampsia 
(CLIP) cluster randomised trials in Mozambique, Pakistan, and India: An individual participant-level meta-
analysis. Lancet, 396(10250), 553-563. 
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_wc/120 
Authors 
Peter Von Dadelszen, Zulfiqar Ahmed Bhutta, Sumedha Sharma, Jeffrey Bone, Joel Singer, Hubert Wong, 
Mrutyunjaya B. Bellad, Shivaprasad S. Goudar, Tang Lee, Rahat Qureshi, and CLIP Trials Working Group 
This article is available at eCommons@AKU: https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_wc/
120 
Articles
www.thelancet.com   Vol 396   August 22, 2020 553
The Community-Level Interventions for Pre-eclampsia (CLIP) 
cluster randomised trials in Mozambique, Pakistan, and India: 
an individual participant-level meta-analysis
Peter von Dadelszen, Zulfiqar A Bhutta, Sumedha Sharma, Jeffrey Bone, Joel Singer, Hubert Wong, Mrutyunjaya B Bellad, Shivaprasad S Goudar, 
Tang Lee, Jing Li, Ashalata A Mallapur, Khátia Munguambe, Beth A Payne, Rahat N Qureshi, Charfudin Sacoor, Esperança Sevene, Marianne Vidler, 
Laura A Magee, and the CLIP Trials Working Group*
Summary
Background To overcome the three delays in triage, transport and treatment that underlie adverse pregnancy outcomes, 
we aimed to reduce all-cause adverse outcomes with community-level interventions targeting women with pregnancy 
hypertension in three low-income countries.
Methods In this individual participant-level meta-analysis, we de-identified and pooled data from the Community-
Level Interventions for Pre-eclampsia (CLIP) cluster randomised controlled trials in Mozambique, Pakistan, and India, 
which were run in 2014–17. Consenting pregnant women, aged 12–49 years, were recruited in their homes. Clusters, 
defined by local administrative units, were randomly assigned (1:1) to intervention or control groups. The control 
groups continued local standard of care. The intervention comprised community engagement and existing community 
health worker-led mobile health-supported early detection, initial treatment, and hospital referral of women with 
hypertension. For this meta-analysis, as for the original studies, the primary outcome was a composite of maternal or 
perinatal outcome (either maternal, fetal, or neonatal death, or severe morbidity for the mother or baby), assessed by 
unmasked trial surveillance personnel. For this analysis, we included all consenting participants who were followed up 
with completed pregnancies at trial end. We analysed the outcome data with multilevel modelling and present data 
with the summary statistic of adjusted odds ratios (ORs) with 95% CIs (fixed effects for maternal age, parity, maternal 
education, and random effects for country and cluster). This meta-analysis is registered with PROSPERO, 
CRD42018102564.
Findings Overall, 44 clusters (69 330 pregnant women) were randomly assigned to intervention (22 clusters 
[36 008 pregnancies]) or control (22 clusters [33 322 pregnancies]) groups. 32 290 (89·7%) pregnancies in the 
intervention group and 29 698 (89·1%) in the control group were followed up successfully. Median maternal age of 
included women was 26 years (IQR 22–30). In the intervention clusters, 6990 group and 16 691 home-based 
community engagement sessions and 138 347 community health worker-led visits to 20 819 (57·8%) of 36 008 women 
(of whom 11 095 [53·3%] had a visit every 4 weeks) occurred. Blood pressure and dipstick proteinuria were assessed 
per protocol. Few women were eligible for methyldopa for severe hypertension (181 [1%] of 20 819) or intramuscular 
magnesium sulfate for pre-eclampsia (198 [1%]), of whom most accepted treatment (162 [89·5%] of 181 for severe 
hypertension and 133 [67·2%] of 198 for pre-eclampsia). 1255 (6%) were referred to a comprehensive emergency 
obstetric care facility, of whom 864 (82%) accepted the referral. The primary outcome was similar in the intervention 
(7871 [24%] of 32 290 pregnancies) and control clusters (6516 [22%] of 29 698; adjusted OR 1·17, 95% CI 0·90–1·51; 
p=0·24). No intervention-related serious adverse events occurred, and few adverse effects occurred after in-community 
treatment with methyldopa (one [2%] of 51; India only) and none occurred after in-community treatment with 
magnesium sulfate or during transport to facility. 
Interpretation The CLIP intervention did not reduce adverse pregnancy outcomes. Future community-level 
interventions should expand the community health worker workforce, assess general (rather than condition-specific) 
messaging, and include health system strengthening.
Funding University of British Columbia, a grantee of the Bill & Melinda Gates Foundation.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
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Pregnancy hypertension (ie, all hypertensive disorders of 
pregnancy, including chronic hypertension, gestational 
hypertension, and pre-eclampsia) complicates appro-
ximately 10% of pregnancies in low-income and 
middle-income countries.1 Pre-eclampsia, the form of 
pregnancy hypertension associated with proteinuria or 
end-organ complications, or both, is associated with the 
greatest risk of maternal, fetal, and neonatal mortality and 
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morbidity.2 Globally, pre-eclampsia is the second leading 
cause of direct maternal mortality, resulting in an 
estimated 76 000 maternal deaths and 500 000 fetal and 
newborn deaths every year.3 More than 99% of these deaths 
occur in low-income and middle-income countries, 
primarily in south Asia and sub-Saharan Africa.4
Generally, research in this field has focused on 
institutional-level interventions with magnesium sulfate 
(for eclampsia prevention and treatment) and paren-
teral antihypertensive therapy for severe hypertension.4 
However, many women die or are irreversibly affected by 
pre-eclampsia because they never reach an inpatient 
facility, either because they die at home or on the way to a 
facility, or because they are already in a critical condition 
on arrival. As such, the concern is that if research 
continues to be restricted to inpatient, facility-level 
interventions, maternal lives will be lost due to pre-
eclampsia and eclampsia from delays in triage, transport, 
and treatment (ie, the so-called three delays).5 A solution 
to these delays might be to provide care to women in 
their communities.
The Community-Level Interventions for Pre-eclampsia 
(CLIP) study (NCT01911494) comprised three cluster 
randomised controlled trials that aimed to reduce the 
burden of adverse maternal and perinatal outcomes 
related to pregnancy hypertension by addressing the 
three delays via community-level intervention. Trial 
design was informed by extensive feasibility studies 
between 2011 and 2014 with pregnant women, mothers, 
household proxy decision makers, health-care workers, 
traditional birth attendants and faith-based caregivers, 
community and opinion leaders, and health adminis-
trators. Literature and document reviews and qualitative, 
quantitative, and participatory methods were used to 
explore the societal context; acceptability of the inter-
vention to women, community health workers (who 
delivered it), and health-care providers (who provided 
support, as required); government stake holders (who 
would support imple mentation); and facility assess-
ment of staff and resources (including commodities). 
Each of the three CLIP trials in India, Pakistan, and 
Mozambique, which were completed, was indepen-
dently powered and designed a priori to contribute to 
an individual participant-level data meta-analysis that 
would improve power for assessment of maternal 
mortality or morbidity, and other components of the 




This individual participant-level meta-analysis included 
data from the CLIP cluster randomised controlled trials 
in India (run from November, 2014, to October, 2016), 
Pakistan (January, 2015, to December, 2016), and 
Mozambique (February, 2015, to February, 2017)7–9 as 
agreed by all CLIP principal investigators (ZAB, MBB, 
SSG, AAM, KM, RNQ, CS, ES) and detailed in the CLIP 
trial protocol. The included trials were cluster randomised 
controlled trials with 12 (India and Mozambique) or 
Research in context
Evidence before this study
We identified evidence from randomised controlled trials of the 
benefit of community mobilisation, task-sharing, and use of 
magnesium sulfate to improve pregnancy outcomes, and 
evidence from observational studies of the use of methyldopa in 
initial management of hypertensive emergencies in volume-
restricted patients (eg, women with pre-eclampsia). 
The individual country Community-Level Interventions for 
Pre-eclampsia (CLIP) trials were done in India, Pakistan, and 
Mozambique between 2014 and 2017 to investigate pregnancy 
hypertension focused and solely community-level community 
engagement, antenatal assessment, risk stratification, initiation 
of life-saving therapies, and transport to hospital.
Added value of this study
The CLIP trials are the first to run a solely community-level 
intervention for pregnancy hypertension, designed to address the 
so-called three delays: triage, transport, and treatment. 
The existing community health workforce was scaled up to 
provide community engagement and community health worker-
led app-guided triage, treatment, and transport to a facility for 
women with pregnancy hypertension. Overall, the CLIP 
intervention did not improve the primary composite of maternal, 
fetal, and newborn mortality and morbidity. Community health 
workers were able to undertake all aspects of the app-guided 
visits, and approximately 10% of pregnant women were found to 
be hypertensive using a device validated for use in pregnancy; 
however, few women were eligible for in-community treatment, 
and the numbers of community health workers were 
inadequate to reach all women who could have benefited. 
An increased number of app-guided visits was associated with 
improved outcomes, with substantial improvements from 
eight such contacts.
Implications of all the available evidence
Our findings suggest that community-level interventions 
addressing triage, initial treatment, and transport of women 
with pregnancy hypertension can be successfully completed by 
community health workers, but their numbers must be 
adequate to provide at least eight antenatal care contacts to 
reduce adverse outcomes. A focus on community-level 
intervention without facility enhancement is unlikely to yield 
the improvements in maternal and perinatal outcome as hoped 
or needed by the global health community. Further studies 
should assess a more comprehensive health strategy that 
involves facility strengthening and community-level activities 
restricted to accurate measurement of blood pressure and 
simple condition-specific interventions.
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20 clusters (Pakistan) comprising complex health system 
interventions.
The Individual Patient Data (IPD) proposal was prospec-
tively registered with PROSPERO, CRD42018102564, as 
were the individual CLIP trials (NCT01911494; the protocol 
is in the appendix [pp 12–120]). Ethical approval for the 
trials and individual participant-level data meta-analysis 
was granted by the University of British Columbia, 
Vancouver, BC, Canada (H12-03497) and each country’s 
relevant research ethics board (Aga Khan University, 
Pakistan, 2590-Obs-ERC-13; KLE University, India, MDC/
IECHSR/2011-12/A-4, ICMR 5/7/859/12-RHN; and Centro 
de Investigação em Saúde da Manhiça [CIBS-CISM/038/14], 
Mozambique National Bioethic Committee [219/CNBS/14]). 
All eligible pregnant women provided written informed 
consent to participate.
Study procedures 
The units of randomisation (clusters) in India were 
primary health centres, in Pakistan were Union Councils 
(in Pakistan, provinces are divided into divisions, sub-
divisions [tehsil], and thereafter into Union Councils, 
comprising a large village and surrounding areas, often 
including nearby small villages) and all associated primary 
health centres, and in Mozambique were Administrative 
Posts (in Mozambique, provinces are divided into districts, 
which are further divided into Administrative Posts). Local 
teams chose potential clusters according to similar health-
care infrastructure, accessibility for the surveil lance team, 
and the absence of conflicting concurrent research acti-
vity. In India and Pakistan, internal pilot trials (each in an 
initial four clusters per country) preceded definitive trials. 
Pregnant women aged 15–49 years (12–49 years in 
Mozambique) were identified in their homes or local 
primary health centres by trained community health 
workers. Clusters were randomly assigned (1:1), via 
restricted, stratified randomisation according to popu-
lation size, to either the intervention or control group. The 
trials were unmasked given the nature of the intervention. 
Partici pants in control clusters continued current local 
practice around antenatal care, referral to facilities, and 
initiation of therapy. The intervention aimed to address the 
so-called three delays in triage, transport, and treatment 
related to maternal mortality risk. The first step was 
community engagement involving women and their 
mothers, household male decision makers, mothers-
in-law, and community leaders regarding pre-eclampsia 
awareness and education about birth preparedness 
and compli cation readiness, supported by culturally 
appropriate pictograms. Community group meetings were 
held in all countries, with additional one-on-one health-
care worker-led meetings in women’s homes in clusters in 
Pakistan. In the second step, community health workers 
were trained to task-share pregnancy-hypertension-
oriented care at CLIP visits in women’s homes, using the 
CLIP Pre-eclampsia Integrated Estimate of Risk (PIERS)-
On-the-Move (POM) mHealth app for risk stratification.10 
The team of community health workers already in place 
was trained to make the intervention scalable, if found to 
improve outcomes in a trial setting.5 Community health 
workers responded to emergency conditions (aided by 
country-specific picto grams), took women’s blood pres-
sure using the Microlife BP 3AS1-2 device (Widnau, 
Switzerland) and assessed dipstick proteinuria at the first 
contact and any subsequent contact when hypertension 
was detected. Per-protocol, the minimum number of CLIP 
visits should have been at least every 4 weeks, with 
additional visits recommended at days 3, 7, and 14 after 
birth. Community health workers were directed by the 
POM app to either administer oral methyldopa 750 mg for 
blood pressure of 160/110 mm Hg or higher; administer 
intramuscular magnesium sulfate 10 g for suspected 
severe pre-eclampsia (miniPIERS11 risk for an adverse 
maternal outcome of at least 25%, severe systolic 
hypertension [at least 160 mm Hg], eclampsia, stroke, or 
vaginal bleeding); or refer the woman to a comprehensive 
emergency obstetric care facility for suspected pre-
eclampsia or increased risk of stillbirth (4+ dipstick 
proteinuria value, or absent fetal movements for at least 
12 h). In referral facilities shared by both intervention and 
control groups, evidence-based care was promoted through 
a small number of continuous profes sional development 
events (three in India, three in Pakistan, and six in 
Mozambique) spaced throughout the trial periods that 
focused on the WHO’s recommendations for prevention 
and treatment of pre-eclampsia and eclamspia.12
In intervention and control clusters, surveillance teams 
were trained to do regular cross-sectional surveys of 
households (every 3–6 months), except in India, where a 
prospective population-based surveillance system was 
established. After individual participant consent was 
obtained, data were collected on baseline individual-level 
and household-level information, antenatal care, and 
adverse maternal, fetal, and neonatal outcomes up to 
6 weeks after birth (for the mother) or 28 days after birth 
(for the neonate). Women were defined as withdrawing 
from the trial if they declined further trial surveillance. 
Women were lost to follow-up if they were more than 
6 weeks post partum (based on estimated delivery date) and 
more than one surveillance cycle from trial end. Women 
were defined as still on follow-up if they either had not 
delivered their baby or were post partum within 6 weeks of 
their estimated delivery date and within one surveillance 
cycle from the trial end. Overall coordination and data 
management was done by the Pre-eclampsia – Eclampsia 
Monitoring, Prevention and Treatment research group at 
The University of British Columbia.7–9
Data analysis
We assessed the risk of bias of each trial according to the 
five criteria for cluster randomised controlled trials in the 
Cochrane Handbook: recruitment bias, baseline imbal-
ance, loss of clusters, incorrect analysis, and comparability 
with individualised randomised trials.13
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Within Research Electronic Data Capture (REDCap; 
version 5, Vanderbilt University, Nashville, TN, USA) we 
extracted data, by trial group, for characteristics of: the 
trial, women enrolled, and the intervention, and outcomes. 
For this meta-analysis, as for the individual trials, the 
primary outcome was one or more of the maternal 
or perinatal mortality or morbidity outcomes, and 
the secondary outcomes were birth preparedness and 
complication readiness, the proportion of births that 
occurred in a facility, and delivery in a facility that is able to 
provide comprehensive emergency obstetric care (panel). 
Secondary outcomes included components of the primary 
Panel: Outcome definitions for Community-Level Interventions for Pre-eclampsia trials and this meta-analysis
Primary outcome
The primary outcome is a combined maternal or perinatal 
outcome (either maternal, fetal, or neonatal death, or severe 
morbidity for the mother or baby).
Maternal outcomes
Maternal death was defined as the number of deaths during 
pregnancy or within 42 days of pregnancy (or last contact day 
if contact was not maintained to 42 days) per 1000 identified 
pregnancies, defined as the maternal death rate.
Maternal morbidity was defined as the number of women with 
one or more life-threatening complication of pregnancy during 
pregnancy or within 42 days of pregnancy or last contact day 
if contact was not maintained to 42 day, per 1000 identified 
pregnancies. Complications of pre-eclampsia were defined as 
follows:
Serious end-organ complications of pre-eclampsia
• Eclampsia: occurrence of generalised convulsions during 
pregnancy, labour, or within 42 days of delivery in the 
absence of epilepsy or another condition predisposing to 
convulsions
• Stroke: hemiparesis, blindness, or both, developed during 
pregnancy or in the 42 days post partum, lasting longer 
than 48 h
• Coma: unconsciousness for ≥12 h
• Antepartum haemorrhage: vaginal bleeding of ≥15 mL with 
or without pain before the onset of labour
• Disseminated intravascular coagulation: abnormal bleeding 
from mucosa (mouth, ears, or both)
Other major causes of maternal mortality
• Obstetric sepsis: in the community, defined as fever and 
one of abdominal or uterine tenderness, foul smelling vaginal 
discharge or lochia, productive cough and shortness of 
breath, dysuria or flank pain, or headache and neck stiffness
• Vesicovaginal or rectovaginal fistula: continuous loss of 
urine, faeces, or both, after delivery
Life-saving interventions
• Cardiopulmonary resuscitation: a set of emergency 
procedures including chest compressions and lung 
ventilation applied in cardiac arrest victims
• Dialysis: haemodialysis, peritoneal dialysis, or both
• Mechanical ventilation (other than for caesarean section): 
intubation and ventilation not related to anaesthesia
• Blood transfusion: one or more units of blood product
• Interventions for major post-partum haemorrhage: 
brace sutures, external and internal uterine compression, 
antishock garment use, internal iliac artery ligation, 
or hysterectomy with or without transfusion
Perinatal outcomes
Perinatal and late neonatal death was defined as stillbirth 
(gestational age ≥20 weeks, ≥500 g, or both), early neonatal 
mortality (within 0–7 days of birth) and late neonatal 
mortality (within 8–28 days of birth) per 1000 identified 
pregnancies.
Neonatal morbidity was defined as occurrence of a primary 
neonatal morbidity during 0–28 days of birth per 
1000 identified pregnancies. Primary neonatal morbidities 
were:
• Feeding difficulty: including inability to suckle normally or 
latch on to the mother’s breast to feed even if the mother’s 
milk is not let down
• Breathing difficulty: including grunting and in-drawing of 
the abdomen under the ribs
• Seizure: occurrence of any seizure event (fits)
• Lethargy: baby not appearing normally wakeful after 
activities such as feeding or sleeping
• Coma: a non-medically induced period of unconsciousness 
of any length
• Hypothermia: baby is cold to touch
• Umbilical cord infection: characterised by discharge from 
and redness around the umbilical stump
• Skin infection: any appearance of abnormally red, black, 
swollen, or blistered skin with pus
• Bleeding from anywhere on the body
• Jaundice: yellow skin and eyes
• CNS-related morbidity: abnormal amount of vomiting as 
defined by the parents or caregiver with bulging or sunken 
fontanelle
Secondary outcomes
Birth preparedness and complications readiness: defined as 
having completed three or more of arranging for transport, 
obtaining prior permission for transport, saving money for 
obstetric care, identifying a skilled birth attendant, and 
identifying a facility for birth.
In-facility birth, defined as any birth at a health-care facility.
Birth at a comprehensive emergency obstetric care facility, 
defined as birth at any centre that provides basic functions and 
capability of doing a caesarean section, giving safe blood 
transfusions, and provision of care for sick and 
low-birthweight neonates, including resuscitation.
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outcome (including a composite of maternal mortality or 
morbidity, and a composite of stillbirth, neonatal death, or 
neonatal morbidity) and safety outcomes. Adverse events 
that we assessed were transport-related injury or death 
and infection-site haematoma or infection after intra-
muscular magnesium sulfate in the community. In India 
(given trial surveillance informed by facility data), we also 
included as part of this meta-analysis maternal systolic 
blood pressure of below 110 mm Hg on arrival at a facility 
after in-community methyldopa; respiratory depression, 
coma, or death during transport after in-community 
magnesium sulfate; and infection-site haematoma or 
infection after intramuscular magnesium sulfate in-
community or at a facility. We were unable to follow up the 
details of a woman’s management and clinical courses 
after she was referred to facility. Serious adverse events 
were defined as being serious, unexpected (in nature, 
severity, or frequency), and thought to be related to the 
study intervention.
For the primary individual participant-level data meta-
analysis, we included all CLIP participants who were 
followed up with regards to the primary outcome of this 
meta-analysis. However, women who withdrew, were lost 
to follow-up, or still on follow-up at trial end were included 
in a sensitivity analysis in which we used the imputation 
from the primary trials in the individual participant-level 
data meta-analysis. Each trial was independent, no 
potential overlap existed between enrolled participants.
With a planned sample size of approximately 
60 600 women in 44 clusters, we would have 80% power 
to find a 20% reduction in the composite maternal and 
perinatal outcome, from a baseline of 10·2% and with 
an intra class correlation coefficient (ICC) of 0·006. 
Furthermore, this sample size would give similar power 
to find a 20% reduction in maternal mortality or 
morbidity if the baseline rate were 1·7% and the ICC 
were less than 0·001 (appendix pp 122–54). A 20% reduc-
tion was chosen a priori as being clinically relevant by 
consensus within the CLIP group of experts and the 
research programme technical advisory group.
We combined data from each trial dataset by study 
group. We summarised data as median (IQR) for con-
tinuous variables and n (%) for categorical variables. While 
in the primary trials we imputed outcomes for women 
with incomplete data, in this meta-analysis we only include 
data from women with complete follow-up.7–9 We assessed 
the treatment effect on the various outcomes using 
generalised mixed-effect models with random effects for 
both country and cluster, and fixed effects for the study 
group and baseline characteristics of maternal age, basic 
education, previous pregnancy (parity), and neonatal 
mortality rate from each country’s baseline survey as part 
of the feasibility studies. We used a one-stage approach, in 
which a single model is fitted directly using the results 
from each study, to make optimal use of data.14 The 
summary statistic was the adjusted odds ratio (OR; fixed 
effect for maternal age, parity [nulliparous vs parous], and 
maternal education, and random effects for country and 
cluster) with Wald-type 95% CI. We assessed between-trial 
heterogeneity using the τ² (estimated as the variance term 
of the random effect for treatment in the mixed-effect 
model) and R² statistics (as the ratio of the SEs of the 
treatment effect from a model with fixed slope and a model 
with a random slope).15 A τ² close to 0 and R² close to 1 
were taken as indicating a lack of heterogeneity. Statistical 
significance (two-sided) was set at a p value of less than 
0·05 for the composite maternal and perinatal outcome, 
and a p value of less than 0·001 for other analyses.
 We did four types of sensitivity analyses for the primary 
outcome and its components to assess the effect of potential 
sources of bias on our results. First, women who were 
defined as lost to follow-up or still on follow-up at the end 
of the trial were included to assess the potential effect of 
missingness. As for the primary analysis of the individual 
CLIP trials, mixed imputation was used to account for the 
risk associated with each woman, depending on her 
personal baseline characteristics, cluster characteristics, 
and time of enrolment relative to the beginning of the trial. 
Second, we restricted the adjusted analysis to women 
whose pregnancies continued to at least 20 weeks, because 
the average gestational age at recruitment was much earlier 
in India (approximately 11 weeks) than in Pakistan (approxi-
mately 21 weeks) and Mozambique (approxi mately 
26 weeks).7–9 As for the individual CLIP trials and according 
to the statistical analysis plan (appendix pp 122–54), 
inclusion for this sensitivity analysis was: restricted to 
women who had 42 days of post-partum follow-up data; 
restricted to women with anticipated birth (according to 
estimated delivery date) or anticipated birth and 42 day of 
post-partum follow-up data within the trial timeline, to 
assess the effect of the intervention independent of 
gestational age at birth; and expanded to include women 
who were enrolled into trial surveillance only post partum, 
which might have reflected an effect of community 
engagement but was a protocol deviation. Third, we did an 
unadjusted analysis without accounting for baseline 
individual-level and cluster-level charac teristics. Fourth, we 
did a so-called on-treatment analysis of women who 
received at least one community health worker-led POM-
guided visit in intervention versus control clusters. 
In an additional planned secondary analysis, we explored 
in the intervention group whether an association existed 
between our primary outcome and the number of CLIP 
visits, measured as 0, 1–3, 4–7, or 8 or more visits, to reflect 
previous and current WHO recommendations for the 
frequency of antenatal care contacts.16 To account for 
factors related to the number of POM-guided visits and 
confounders, the analysis was restricted to women whose 
pregnancies continued beyond 20 weeks and was adjusted 
for maternal age, basic education, parity, time of enrol-
ment in the trial, and distance from the household to a 
facility.
We used R statistical software (version 3.5.2) for all 
analyses.
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Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all data in the study and final responsibility for the 
decision to submit for publication.
Results
The general characteristics of the CLIP trials, their 
participants, intervention implementation, and outcomes 
are presented in the appendix (pp 4–5).
In the three CLIP trials, comprising 44 clusters 
(n=22 intervention, n=22 control), 69 330 participants 
were enrolled (36 008 pregnancies in the intervention 
group and 33 322 in the control group), some of whom 
were pregnant more than once, such that we had a 
third more births than expected per cluster (appendix 
pp 11–121). 61 988 (89·4%) pregnancies were successfully 
followed up (32 290 [89·7%] in the inter vention group 
and 29 698 [89·1%] in the control group), at similar and 
high rates across countries (appendix pp 4–5). Few 
women withdrew from the study (four [<0·1%] in the 
intervention group and five [<0·1%] in the control 
group). Loss to follow-up, which only occurred in 
Pakistan and Mozambique, was slightly lower (by 0·7%) 
in intervention clusters; loss to follow-up was attributed 
to migration and cyclical surveillance cycles by study 
site staff. Just under 8% of pregnancies (2811 [7·8%] in 
the intervention group and 2555 [7·7%] in the control 
group) were ongoing and still on follow-up on the trial 
end date.
The median maternal age of included women was 
26 years (IQR 22–30) across all countries (appendix 
pp 4–5). Basic education, as measured by each country, 
had been received by over 60% of women in India (ie, at 
least 8 years of schooling) and Mozambique (ie, at least 
grade 5), but by no more than 20% in Pakistan (ie, at least 
5 years of schooling). Overall, over 70% of women in all 
countries were parous. The median gestational age at 
trial enrolment was 19·0 weeks (IQR 12·5–26·8), with 
the earliest in India (approximately 11 weeks), followed 
by Pakistan (approximately 21 weeks) and Mozambique 
(approximately 27 weeks).
23 681 (6990 group and 16 691 home-based) community 
engagement sessions were held by the CLIP country 
teams (appendix pp 4–5). Training (of 2–15 days’ duration) 
was delivered to 450 health-care providers, with refresher 
training every 1–6 months. Methyldopa and magnesium 
sulfate were sourced in-country. Trained community 
health workers provided 138 347 visits for a median of 
six visits per pregnancy, four (IQR two to six) antenatal 
and two (IQR one to three) post partum. 20 819 (57·8%) of 
36 008 women in the intervention group had one or more 
POM-guided visits, approximately half of whom had 
visits that were compliant with the minimum frequency 
(11 095 [53·3%] of 20 819). Blood pressure was measured 
at almost all visits (137 705 [99·5%]), and dipstick 
proteinuria was done at 21 257 [96·4%] of 22 051 relevant 
visits as per the protocol (ie, first and all subsequent visits 
at which hypertension was detected). POM-guided 
visits resulted in recommendations at 136 755 (98·9%) 
visits. As previously published, hypertension was iden-
tified in 2111 [9·9%] of 21 306 pregnancies (636 [10·3%] of 
6149 in India; 1010 [9·3%] of 10 904 in Pakistan; 
and 465 [10·9%] of 4253 in Mozambique).1 181 (0·9%) of 
20 819 women were eligible for treatment with oral 
methyldopa for severe hypertension and 198 (1·0%) were 
eligible for intramuscular magnesium sulfate for pre-
eclampsia, and 1255 (6·0%) women were referred to a 
facility. Most women accepted the community health 
workers’ POM-guided recommendations to administer 
oral methyldopa (162 [89·5%] of 181 eligible pregnancies) 
and intramuscular magnesium sulfate (133 [67·2%] of 
198), and referral to a comprehensive emergency obstetric 
care facility (864 [81·6%] of 1255 pregnancies with recom-
mended referral).
Protocol deviations occurred in few pregnancies 
(295 [0·9%] of 32 290) in the intervention group, of 
which 46 (15·6%) were related to treatment or referral 
not recommended as per the POM app and protocol 
(n=40 in India, n=4 in Pakistan, and n=2 in Mozambique) 
and 249 (84·4%) were antenatal CLIP visits by the 
community health workers among women only enrolled 
by the trial surveillance team during their post-partum 
period (n=6 in India, n=23 in Pakistan, and n=220 in 
Mozambique); pregnancies that had protocol deviations 
did not result in withdrawals or adverse events.
No effect of the CLIP intervention was seen on the 
primary composite maternal and perinatal outcome 
(7871 [24·4%] pregnancies in intervention group had 
one or more of the predefined maternal or perinatal 
mortality or morbidity outcomes vs 6516 [21·9%] 
pregnancies in the control group; adjusted OR 1·17, 
95% CI 0·90–1·51) or its components, as was the case in 
each included cluster randomised controlled trial 
(table 1, figure).7–9 Most events were morbidities for the 
mother (6062 [9·8%] of 61 998 pregnancies) and neonate 
(6299 [10·2%]). Death was rare for mothers (143 [0·2%]), 
but not so for fetuses and neonates, with similar rates of 
stillbirth (2591 [4·2%]) and neonatal death (2677 [4·3%]). 
The ICC was 0.059. Similar patterns were seen across 
countries (appendix pp 4–5). The intervention had no 
effect on secondary outcomes (table 1). Approximately 
half of women in both groups showed birth preparedness 
and compli cation readiness. Most women delivered in 
a facility, with approximately half of women overall 
delivering in a comprehensive emergency obstetric care 
facility. We found no evidence of between-trial hetero-
geneity in outcomes. The gestational age at delivery was 
39 weeks (IQR 37–41) for both intervention and control 
clusters.
No serious adverse events related to the intervention 
or study occurred (appendix p 5) and few adverse events 
occurred. In one (2·0%) of 51 women in the intervention 
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group in India, in-community receipt of methyldopa was 
associated with a decrease in blood pressure from a 
median of 167/108 mm Hg (IQR 162/100 to 178/113) to 
160/100 mm Hg (146/90 to 170/110) after a median of 
97 min (75–150). Injection-site haematoma or infection 
was reported only after receipt of magnesium sulfate in-
facility (four [2·4%] of 168 in intervention group vs 
1386 [3·5%] of 26 698 in the control group, in India only) 
and none was reported after in-community administra-
tion. No injuries related to transport to facility occurred.
Recruitment bias was regarded as low in all included 
trials. Although participants and their care providers were 
aware of their assignment to intervention or control 
clusters in this complex health system intervention study, 
enrolment in the trials was based on household residence. 
Clusters were defined by the unit of the primary health-
care system associated with a woman’s household; 
therefore, she could not simply choose to participate 
in another study area. Enrolment was slightly higher 
(by 8·7%), and loss to follow-up lower (by 0·7%) in 
intervention clusters than in control clusters (p<0·0001), 
which could cause concern about the risk of bias 
associated with baseline imbalances in the clusters. In 
India, one cluster was replaced by another with similar 
characteristics early in the pilot phase, and clearly before 
data analysis, in response to issues with primary health 
centre leadership and data integrity; otherwise, there 
were no concerns related to loss of clusters, incorrect 
analysis, or variability between clusters (because each 
trial accounted for clustering and reported ICC for each 
outcome).
In sensitivity analyses, the CLIP intervention had no 
effect when data for women defined as lost to or still 
on follow-up were imputed, unadjusted for baseline 
maternal characteristics, restricted to women whose 
pregnancies continued to at least 20 weeks, or in our 
on-treatment analysis restricted to women who received 
at least one community health worker-led POM-guided 
visit (adjusted OR 1·12, 95% CI 0·86–1·47, p=0·40; 
Event rate Adjusted odds 
ratio*





Primary composite maternal and 
perinatal outcome†
7871 (24·4%) 6516 (21·9%) 1·17 (0·90–1·51) 0·24 0·007 1·08
Maternal outcome 3369 (10·4%) 2781 (9·4%) 1·20 (0·84–1·74) 0·32 0·003 1·01
Maternal mortality 77 (0·2%) 66 (0·2%) 1·05 (0·67–1·64) 0·84 0·002 1·24
Maternal morbidity 3319 (10·3%) 2743 (9·2%) 1·20 (0·83–1·74) 0·32 0·003 1·00
Perinatal mortality, late neonatal 
death, or neonatal morbidity
5618 (17·4%) 4760 (16·0%) 1·10 (0·89–1·37) 0·38 0·003 1·06
Stillbirth 1322 (4·1%) 1269 (4·3%) 1·03 (0·89–1·19) 0·69 0·003 1·00
Neonatal mortality 1408 (4·4%) 1269 (4·3%) 1·10 (0·96–1·27) 0·17 0·005 1·44
Neonatal morbidity 3463 (10·7%) 2836 (9·5%) 1·09 (0·73–1·62) 0·69 0·025 1·12
Secondary outcomes
Birth preparedness and 
complication readiness‡
15 875 (53·4%) 13 530 (45·5%) 0·91 (0·41–2·02) 0·82 0·001 1·01
Proportion of facility births 25 397 (85·5%) 23 282 (78·7%) 1·06 (0·82–1·36) 0·66 0·01 1·13
Birth at a comprehensive 
emergency obstetric care 
facility
14 657 (49·3%) 14 398 (48·5%) 0·84 (0·59–1·19) 0·32 0·001 1·01
Data are n (%) or adjusted odds ratio with 95% CI in parentheses, unless otherwise stated. τ² is estimated as the variance term of the random effect for treatment in the mixed 
effect model and R² is the ratio of the SEs of the treatment effect from a model with fixed slope and one with a random slope. CLIP=Community-Level Interventions for 
Pre-eclampsia. *Adjusted for maternal age, parity, and maternal basic education. †Defined as one or more of maternal morbidity or mortality, stillbirth, neonatal mortality, 
or neonatal morbidity; the primary outcome in the CLIP trials. ‡Birth preparedness was defined as a “Yes” answer to all of the following: arranged for transport, obtained prior 
permission to seek emergency care, and saved money for obstetric care.
Table 1: Primary and secondary outcomes
Figure: Forest plot of primary composite outcome and its components in 
each CLIP trial and overall
Data points are adjusted odds ratios with 95% CIs indicated with whiskers. 





Favours intervention Favours control
1·00
Adjusted odds ratio
0·75 1·25 1·50 1·75 2·00
Country
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appendix p 6). However, there was an association 
between number of visits and outcomes (table 2). Fewer 
women with eight or more CLIP visits had a CLIP 
primary outcome or its components than those with 
no visits, an effect that was seen in each of the three 
countries (table 2; appendix p 8). The exception was 
neonatal morbidity, which was increased among those 
with eight or more visits (vs no visits) and not associated 
with a difference in gestational age at delivery (median 
39 weeks in both intervention and control clusters; 
appendix p 9). Women with four to seven visits had an 
incidence of outcomes that were intermediate between 
those with eight or more visits and those with one to 
three visits. However, women with one to three visits 
had more adverse perinatal outcomes than did women 
without a POM-guided visit; we have previously reported 
that these women were enrolled 2–4 weeks earlier than 
those without a POM-guided visit, but we did not identify 
other baseline differences.7–9
Discussion
The three CLIP cluster randomised controlled trials in 
India, Pakistan, and Mozambique involved just over 
60 000 pregnancies in 44 clusters. 23 681 community 
engagement sessions were run, in groups in all countries 
and one-on-one with women and their immediate 
community in Pakistan. Community health workers 
proficiently carried out POM-guided visits for pregnant 
women in their communities, successfully measuring 
blood pressure and proteinuria, and providing POM app-
guided triage and initial treatment of severe hypertension 
(with methyldopa) and suspected severe pre-eclampsia 
(with magnesium sulfate). Nevertheless, our community-
level intervention for pregnancy hypertension had no 
effect on a composite of all-cause maternal and perinatal 
mortality or morbidity compared with care as usual, as 
observed in the individual country-level trials.7–9
Our findings are unlikely to be related to low statistical 
power, despite our higher than anticipated ICC (ie, 0·059 
vs 0·006 anticipated). The event rate (14 387 [23·2%] of 
61 988 pregnancies) was higher than anticipated (10·2%), 
as it was for the combined maternal outcome of maternal 
mortality and morbidity (ie, 6150 [9·9%] of pregnancies vs 
1·7% anticipated). Also, the 95% CI of the adjusted OR of 
the combined outcome and its maternal, fetal, and 
neonatal components did not include the 20% reduction 
considered a priori to be important.
The CLIP intervention did not reach all women who 
could have benefited from it. First, only about two-thirds 
of women enrolled in intervention clusters received at 
least one CLIP visit, and just over half of these women 
had visits at the target frequency of once every 4 weeks. 
This limitation in human resource capacity in study 
areas came from our decision to use the existing 
community health worker workforce for scalability. 
However, expansion of this workforce might be 
worthwhile given that a higher number of POM-guided 
CLIP visits reduced the odds of the composite primary 
outcome and its components, other than survivable 
neonatal morbidity, which increased. This benefit was 
seen with eight or more visits, consistent with the WHO 
recommendations for eight antenatal care contacts.16 
Second, the POM-guided care algorithm focused on 
referrals for systolic hypertension, detected in 1255 visits 
(0·9% of 138 347 visits; 6·0% of 20 819 pregnancies). 
This approach was taken to direct resources to women at 
highest risk of stroke and not overwhelm referral 
facilities, and to enable measurement of blood pressure 


















Primary outcome‡ 2928 (27·2%) 1 (ref) 1251 (29·0%) 1·07 (0·98–1·18) 0·16 2340 (26·1%) 0·95 (0·88–1·03) 0·21 1242 (18·6%) 0·88 (0·80–0·97) 0·0079
Maternal outcome 1246 (11·6%) 1 (ref) 539 (12·5%) 0·96 (0.84–1·08) 0·49 1040 (11·6%) 0·92 (0·82–1·02) 0·11 436 (6·5%) 0·86 (0·74–0·99) 0·032
Maternal 
mortality
24 (0·2%) 1 (ref) 11 (0·3%) 0·96 (0·42–2·18) 0·92 14 (0·2%) 0·57 (0·28–1·19) 0·14 5 (0·1%) 0·32 (0·11–0·92) 0·035
Maternal 
morbidity
1229 (11·5%) 1 (ref) 535 (12·4%) 0·97 (0·86–1·10) 0·63 1032 (11·5%) 0·93 (0·83–1·03) 0·16 435 (6·5%) 0·87 (0·76–1·01) 0·060
Fetal or neonatal 
adverse outcome
2132 (19·9%) 1 (ref) 922 (21·5%) 1·16 (1·05–1·28) 0·0047 1634 (18·2%) 0·96 (0·88–1·05) 0·37 928 (13·9%) 0·86 (0·77–0·95) 0·0037
Stillbirth 505 (4·7%) 1 (ref) 279 (6·5%) 1·54 (1·30–1·81) <0·0001 396 (4·4%) 0·88 (0·76–1.02) 0·098 142 (2·1%) 0·41 (0·33–0·51) <0·0001
Neonatal 
mortality
545 (5·3%) 1 (ref) 260 (6·5%) 1·34 (1·14–1·58) 0·0005 414 (4·8%) 0·93 (0·81–1·08) 0·35 188 (2·9%) 0·66 (0·54–0·81) <0·0001
Neonatal 
morbidity
1266 (11·8%) 1 (ref) 485 (11·3%) 0·87 (0·76–0·99) 0·034 986 (11·0%) 0·99 (0·89–1·10) 0·79 725 (10·9%) 1·24 (1·09–1·41) 0·0016
 Data are number of events and proportion of total events by visit number category, and adjusted odds ratio with 95% CI in parentheses, unless otherwise stated. CLIP=Community-Level Interventions for 
Pre-eclampsia. POM=Pre-eclampsia integrated estimate of risk-On-the-Move. *These analyses included the 30 721 women in intervention clusters who were followed-up, excluding the 1341 women who were 
followed-up (ie, excluding 1341 women from the total population who were recruited and had a miscarriage before 20 weeks). †Adjusted for maternal characteristics (as in the primary analysis: maternal age, 
parity, basic education, and gestational age at enrolment; enrolment timing in the trial; and distance from the household to facility. ‡Defined as one or more of maternal morbidity or mortality, stillbirth, 
neonatal mortality, or neonatal morbidity; the primary outcome in the CLIP Trials.
Table 2: Sensitivity analysis of the association between number of community health-care worker POM-guided CLIP visits and the primary outcome among 30 721 pregnancies in CLIP*
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by palpation (using an inflatable cuff) given inadequate 
access to accurate and affordable equipment in our study 
settings. However, in this young maternal population, 
isolated diastolic hypertension predominated (1314 [62%] 
of 2111 women with hyper tension),1 and the blood pres-
sure device used in CLIP has proven to be both usable 
and affordable.17 Whether referral of more women with 
hypertension to the relevant facilities would have been 
possible without overwhelming their scarce resources, or 
whether com munity-level treatment of hypertension 
could have improved outcomes is unknown.
Despite the importance of hypertension as a cause 
of maternal and perinatal mortality and morbidity, 
treatment of severe hypertension and use of magnesium 
sulfate for eclampsia prevention were aspects of the 
CLIP intervention for which only a small proportion of 
women were eligible. Despite the evidence base for 
effectiveness and safety of these treatments18,19 and shown 
safety in our study settings, the rarity that women were 
eligible to receive them makes the likelihood that these 
treatments would have had an effect on outcomes overall 
is low. Notably, considerable training and permissions for 
task-sharing are required for community health workers to 
admini ster intramuscular magnesium sulfate. Although 
oral methyldopa for severe hypertension was indicated 
for a similarly small proportion of women, adminis-
tration was straightforward, which raises the potential 
for community-level treatment of low-risk hypertension 
(ascertained by miniPIERS risk prediction11) and managed 
by a simple antihypertensive algorithm.20 By contrast, 
blood pressure measurement, using the Microlife 
BP 3AS1-2 device validated for use in preg nancy, showed 
that at least 10% of women in our study settings had 
pregnancy hypertension that was usually gestational 
hypertension without proteinuria, a condition amenable to 
enhanced surveillance and timed delivery.1
This individual participant-level meta-analysis is a novel 
meta-analysis of trials testing a combination of com-
munity engagement and mHealth-supported task-sharing 
with community health workers focused on pregnancy 
hypertension. In a 2015 Cochrane review of community-
based interventions in pregnancy,21 eight of 26 cluster 
randomised controlled trials included studied a package 
of community mobilisation and home visits. Six of these 
cluster randomised controlled trials were in India or 
Pakistan. Three cluster randomised controlled trials 
focused on home counselling and education22,23 or home 
visits by traditional birth attendants who inquired 
about warning symptoms of pregnancy complications.24 
However, five cluster randomised controlled trials focused 
on newborn interventions25–29 and five focused on 
strengthened labour and delivery care, with or without 
provision of clean delivery kits.24,25,27–30 Community-based 
intervention packages were associated with a non-
significant decrease in maternal mortality and significant 
decreases in maternal morbidity, stillbirth, and neonatal 
mortality; neonatal morbidity was not reported.21 The 
decrease in maternal morbidity was driven by results of 
one trial in Pakistan where the traditional birth attendants 
received clean delivery kits and strengthened the provision 
of facility care in the intervention group.24 By contrast, the 
CLIP trials used community-level hyper tension-focused 
ante natal care, with minimal facility-enhanced quality of 
care in both intervention and control groups. With regards 
to the reduction in stillbirth, two of three trials provided 
broad additional antenatal care training to community 
health workers who also worked with traditional birth 
attendants to enhance the quality of labour and delivery 
care.27,28 CLIP focused only on pregnancy hypertension-
related antenatal care with minimal facility enhancement 
in all clusters. Finally, five of six trials that reported 
neonatal mortality had newborn care as part of the 
intervention.25,27–30 CLIP focused entirely on community-
level interventions for the mother and fetus, but not for 
the neonate.
Strengths of our analysis include the planned meta-
analysis and harmonisation of study processes and 
outcome definitions; the large size of the trial popula-
tions and comprehensive recruitment of almost all 
eligible unselected pregnant women to mirror routine 
antenatal care; successful implementation of community 
health worker-led POM-guided antenatal care visits 
oriented around hypertension in women’s community 
with regards to reach and fidelity; that the intervention 
and outcome assessment were done by different teams; 
and the consistency of findings across three countries. 
Limitations include potential ascer tainment bias, which 
cluster randomised controlled trials are susceptible to; 
nevertheless, any difference in recruitment and loss to 
follow-up in intervention clusters was very small. 
Another limitation is our reliance on the existing 
community health-care work force, which affected the 
extent to which the intervention could be delivered. 
Although designed to reflect the scalability and 
sustainability of the intervention, our study has 
emphasised that the health systems at our study sites are 
currently inadequate to implement a complex, condition-
specific, community-level interven tion. A focus on the 
community without facility enhancement was an 
additional limitation, but we have gathered unique 
information about the merits of community-level inter-
vention in isolation. We were unable to assess the effect 
of the CLIP visit content on outcomes. Strengths of 
the CLIP visit content were that blood pressure and 
proteinuria were measured at almost all relevant visits 
and that community health workers were proficient with 
the POM app; however, the number of women who were 
eligible to receive oral methyldopa or intramuscular 
magnesium sulfate was too small to make an analysis of 
acceptance of in-community treatment feasible. A full 
process evaluation is planned to explore more compre-
hensively the context (including cost), implementation, 
and mechanisms of effect of our intervention in each of 
the three CLIP countries.31
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Management and detection of pregnancy hypertension 
provide a gateway to excellence in maternity care. Ideally 
a health system should be able to identify and respond to 
pregnancy hypertension, induce labour, and provide 
both safe caesarean deliveries and care in the post-
partum period. Achievement of these markers of good 
quality maternity care would contribute substantially to 
achievement of Sustainable Development Goal 3.1.
In summary, our findings suggest that community-
level intervention addressing triage, initial treatment, 
and transport of women with pregnancy hypertension 
can be successfully implemented by community health 
workers, but their numbers must be adequate to provide 
at least eight antenatal care contacts to reduce adverse 
outcomes. Even then, the reduction is not large, sug-
gesting that a focus only on community-level inter-
vention without facility enhancement is unlikely to yield 
the improvements in maternal and perinatal outcome 
as hoped or as needed by the global health community. 
Further study should include community-level care 
restricted to adequate measurement of blood pressure 
and simple condition-specific interventions as part of a 
comprehensive health-strengthening programme.
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